TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36620632
Drug: Antibacterial envelopes
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial envelopes without adjunct IV ABX
Study: 36620634
Drug: Edoxaban administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban administered through PEG at approved doses
Study: 36620770
Drug: Standard-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose atorvastatin (not specified)
Study: 36620965
Drug: Inclisiran (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (300 mg subcutaneous, twice-yearly)
Study: 36620965
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg subcutaneous, every 2 weeks for 360 days, then inclisiran twice-yearly)
Study: 36621000
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) 10 mg/kg on Days 1 and 8 of each 21-day treatment cycle until disease progression/unacceptable toxicity
Study: 36621142
Drug: Previous systemic
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous systemic therapies (specifically protein kinase inhibitors)
Study: 36621265
Drug: Online survey
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online survey for parents regarding recipe preparation.
Study: 36621830
Drug: DS-1205c monotherapy
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1205c monotherapy (200-1200 mg BID) followed by combination therapy with DS-1205c (800 mg BID) and gefitinib (250 mg once daily)
Study: 36621830
Drug: DS-1205c (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1205c (800 mg BID) in combination with gefitinib (250 mg once daily)
Study: 36622402
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (60 mg FTD/TPI, 20 mg tablet, 3 tablets)
Study: 36622402
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Lonsurf)
Study: 36622462
Drug: no-basic Therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: no-basic Therapy Intensity Level (TIL)
Study: 36622462
Drug: extreme Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: extreme Therapy Intensity Level (eTIL)
Study: 36622462
Drug: mild-moderate Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: mild-moderate Therapy Intensity Level (TIL)
Study: 36622462
Drug: Therapy Intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy Intensity Level (TIL)
Study: 36622539
Drug: Tecarfarin 10
Normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecarfarin 10 mg
Study: 36622539
Drug: Tecarfarin 20
Normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecarfarin 20 mg
Study: 36622539
Drug: Tecarfarin 40
Normalized name: Tecarfarin
DrugBank: Tecarfarin (DB12823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecarfarin 40 mg
Study: 36622539
Drug: Tecarfarin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecarfarin (all doses)
Study: 36622653
Drug: Internet-delivered parent-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered parent-child interaction therapy (iPCIT) for 20 weeks
Study: 36622653
Drug: Internet-delivered parent-child
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered parent-child interaction therapy (iPCIT)
Study: 36622674
Drug: Usual pharmacy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Usual pharmacy care focused on medication adherence
Study: 36622798
Drug: Daily PrEP
Normalized name: Zinc Oxide 238 mg in 1 mL / Titanium Dioxide 41 mg in 1 mL TOPICAL LOTION [bareMinerals Prep Step Mineral Shield Broad Spectrum SPF 50 Daily Prep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PrEP dosing (90 days) followed by 1 to 7 doses/week (90 days)
Study: 36623230
Drug: 70-Gy once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70-Gy once-daily radiotherapy
Study: 36623230
Drug: 45-Gy twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45-Gy twice-daily radiotherapy
Study: 36623241
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg once every 3 weeks for 6 months
Study: 36623246
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy APBI (38.5 Gy/10 fraction twice daily)
Study: 36623517
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (100 U/mL) once daily with mealtime insulin aspart (100 U/mL)
Study: 36623517
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (100 U/mL) once or twice daily with mealtime insulin aspart (100 U/mL)
Study: 38141256
Drug: Ritlecitinib 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 20 mg
Study: 38141256
Drug: Ritlecitinib 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 70 mg
Study: 38141256
Drug: Ritlecitinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 200 mg
Study: 36623678
Drug: Brepocitinib 10
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib 10 mg
Study: 36623678
Drug: Brepocitinib 30
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib 30 mg
Study: 36623678
Drug: Brepocitinib 60
Normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Brepocitinib 60 mg
Study: 36624219
Drug: LXS196 100-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LXS196 100-1000 mg once daily (QD), n=38
Study: 36624219
Drug: LXS196 200-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: LXS196 200-400 mg twice daily (BID), n=30
Study: 36624252
Drug: Standard D-Dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard D-Dimer threshold of 500 ng/mL
Study: 36624292
Drug: Ipilimumab (IPI)
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab (IPI) at 1 mg/kg and Nivolumab (NIVO) at 3 mg/kg combined with Melphalan Percutaneous Hepatic Perfusion (M-PHP) at 3 mg/kg (maximum of 220 mg) for 12 weeks.
Study: 36624312
Drug: Highest dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dosage of hfNPCs
Study: 36624391
Drug: Chemsex-associated drug
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemsex-associated drug users
Study: 36624483
Drug: Postoperative proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative proton beam therapy
Study: 36624526
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) - 30 mg/kg loading dose, then 1 mg/kg/h for 12 hours
Study: 36624526
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline) - identical intravenous administration as bolus and continuous infusion
Study: 36624598
Drug: Unilateral vestibular
Normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral vestibular implantation with an investigational multichannel vestibular implant
Study: 36624727
Drug: velusetrag 5
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: velusetrag 5 mg
Study: 36624727
Drug: velusetrag 30
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: velusetrag 30 mg
Study: 36624727
Drug: velusetrag (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: velusetrag (all doses)
Study: 36625502
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose to the ipsilateral lateral pterygoid muscle above the median value (36.8 grays)
Study: 36625831
Drug: Cogstate computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cogstate computerized battery during chemotherapy and 1-year post-treatment
Study: 36625894
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg every 2 weeks) plus cabozantinib (40 mg/day)
Study: 36625894
Drug: Dose modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose modification strategies for cabozantinib
Study: 36626020
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise group (SEG) performing twice weekly moderate- to high-intensity training
Study: 36626107
Drug: Dupilumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab treatment initiated according to country-specific prescribing information, per physician discretion as part of routine care.
Study: 36626198
Drug: 1-year follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year follow-up after treatment.
Study: 36627013
Drug: Alkylating agent-based
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agent-based regimen
Study: 36627013
Drug: Alkylating agent-based
Normalized name: petroleum alkylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkylating agent-based regimen with POI without HRT
Study: 36627156
Drug: Mindful SensoriMotor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful SensoriMotor Therapy (MiSMT) combined with transcranial direct current stimulation (tDCS)
Study: 36627157
Drug: Digital pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital pill system (ID-capsule manufactured by etectRX, named My/Treatment/Pill)
Study: 36627285
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) with Adriamycin and cyclophosphamide (AC)
Study: 36627285
Drug: Experimental therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapies and/or additional chemotherapy post-NACT
Study: 36627655
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg once daily (sensitivity analysis)
Study: 36628573
Drug: Ipilimumab-nivolumab combination
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab-nivolumab combination
Study: 36628898
Drug: Fruquintinib 5
Normalized name: fruquintinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5 mg once daily (2 weeks on/1 week off) plus sintilimab 200 mg Q3W
Study: 36628898
Drug: Fruquintinib 5
Normalized name: fruquintinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib 5 mg once daily (2 weeks on/1 week off) plus sintilimab 200 mg Q3W in mismatch repair-proficient mCRC
Study: 36630120
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous sodium selenite (2000 μg/L prior to cardiopulmonary bypass, 2000 μg/L immediately postoperatively, and 1000 μg/L daily for up to 10 days)
Study: 36630140
Drug: Lebrikizumab (LEB)
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab (LEB) + Topical Corticosteroids (TCS)
Study: 36630140
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) + Topical Corticosteroids (TCS)
Study: 36630319
Drug: Sublingual dexmedetomidine
Normalized name: dexmedetomidine Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dexmedetomidine (BXCL501)
Study: 36630619
Drug: Compassion-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-focused therapy
Study: 36630958
Drug: LY3463251 (GDF15
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3463251 (GDF15 receptor agonist)
Study: 36630958
Drug: LY3463251 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3463251 (single subcutaneous injection)
Study: 36630958
Drug: LY3463251 (12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3463251 (12-week multiple ascending dose study)
Study: 36631449
Drug: Pevonedistat (TAK924)
Normalized name: Pevonedistat
DrugBank: Pevonedistat (DB11759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pevonedistat (TAK924) given intravenously on days 1, 3, 5 of a 21-day cycle for 8 cycles at five dose levels (15 to 50 mg/m2)
Study: 36631545
Drug: FLT190 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FLT190 gene therapy (AAV2/S3-FRE1-GLAco) administered as a single intravenous dose in murine model and non-human primates (NHPs)
Study: 36631545
Drug: FLT190 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FLT190 gene therapy (AAV8-FLT190) in Fabry mice
Study: 36631545
Drug: FLT190 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FLT190 gene therapy in NHPs
Study: 36631592
Drug: Fully closed-loop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully closed-loop insulin delivery (no meal bolusing)
Study: 36631687
Drug: Levosimendan (LVSMD)
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (LVSMD) infusion at 0.2 µg/kg/min over 24 hours
Study: 36631687
Drug: Levosimendan (LVSMD)
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (LVSMD) infusion over 48 hours instead of 24 hours
Study: 36631720
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec (5.6 U/kg) administered subcutaneously in the thigh
Study: 36631720
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec (5.6 U/kg) administered subcutaneously in the abdomen
Study: 36631720
Drug: Insulin icodec
Normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin icodec (5.6 U/kg) administered subcutaneously in the upper arm
Study: 36631831
Drug: Volatile agent
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile agent
Study: 36631895
Drug: Light breakfast
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light breakfast (14 g protein, 2218 kJ)
Study: 36632738
Drug: Venetoclax and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax and rituximab (VenR) combination treatment
Study: 36632758
Drug: MIP (metamizole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIP (metamizole, ibuprofen, paracetamol)
Study: 36632758
Drug: i.p. (ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.p. (ibuprofen and paracetamol)
Study: 36632983
Drug: Teriflunomide (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide (14 mg adult equivalent)
Study: 36633115
Drug: Long-acting opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting opioids (intravenous morphine 30 min before emergence from anaesthesia)
Study: 36633505
Drug: ADO09 (pramlintide/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADO09 (pramlintide/insulin A21G)
Study: 36633570
Drug: 9.6 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9.6 mg/dose carbetocin
Study: 36633570
Drug: 3.2 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg/dose carbetocin
Study: 36633816
Drug: Vericiguat 10
Normalized name: vericiguat 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat 10 mg once daily (up-titrated from 2.5 mg to 5 mg to 10 mg at 14-day intervals)
Study: 36633816
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg (single dose on day 8 or day 50)
Study: 36633838
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg twice daily for 10 days)
Study: 36633844
Drug: ML recommender
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML recommender
Study: 36633868
Drug: Behavioral nudges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral nudges to clinicians including weekly emails comparing SIC rates, weekly lists of high-risk patients, and opt-out text messages to prompt SICs before encounters.
Study: 36634920
Drug: Pixatimod 25
Normalized name: pidotimod
DrugBank: Pidotimod (DB11364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pixatimod 25 mg plus nivolumab 240 mg
Study: 36635304
Drug: β2-agonist treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: β2-agonist treatment
Study: 36635764
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment in a single visit (RCT-SV)
Study: 36635764
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment in two visits with intracanal dressing (RCT-TVWD)
Study: 36635764
Drug: Root canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root canal treatment in two visits without intracanal dressing (RCT-TVWOD)
Study: 36636296
Drug: Single, moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, moderate dose of psilocybin (0.215 mg/kg body weight)
Study: 36636739
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 μg, subcutaneous)
Study: 36636751
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy using a paper book of exercises (3 hours/week for 3 weeks)
Study: 36636993
Drug: Emicizumab administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab administration
Study: 36637153
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 mg, 10 mg, 5 mg, 2.5 mg, 1 mg)
Study: 36637153
Drug: Tamoxifen (low-dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (low-dose: 2.5-5 mg)
Study: 36637153
Drug: Tamoxifen (high-dose:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (high-dose: 10-20 mg)
Study: 36637209
Drug: Prednisolone (∼0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (∼0.3 mg/kg) for 6 months
Study: 36638837
Drug: CSCC_ASC injections
Normalized name: ASC-618
DrugBank: ASC-618 (DB18423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSCC_ASC injections
Study: 36639200
Drug: FGFR3 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FGFR3 inhibitor
Study: 36639249
Drug: diazoxide choline
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazoxide choline extended-release tablet (DCCR)
Study: 36639328
Drug: Ephedrine 1.2
Normalized name: ephedrine 1.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 1.2 mg kg
Study: 36639328
Drug: Ephedrine doses
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ephedrine doses much higher than those used in adults (∼10-fold)
Study: 36639636
Drug: Grades 3-4
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grades 3-4 hyperbilirubinemia during induction/consolidation treatment
Study: 36639636
Drug: Grades 1-2
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grades 1-2 hyperbilirubinemia during induction/consolidation treatment
Study: 36639636
Drug: Grade 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 0 hyperbilirubinemia during induction/consolidation treatment
Study: 36640127
Drug: MDNA55 (interleukin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDNA55 (interleukin 4 receptor-targeting toxin) administered intratumorally as a single dose treatment (dose range of 18 to 240 μg) using convection-enhanced delivery (CED).
Study: 36640127
Drug: High-dose MDNA55
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose MDNA55 (>180 μg) in a subgroup of IL4R High and IL4R Low patients.
Study: 36640127
Drug: MDNA55 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MDNA55 treatment in evaluable patients (n=32) based on mRANO criteria.
Study: 36640137
Drug: NHS-IL12 12
Normalized name: (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHS-IL12 12 µg/kg SC q2w
Study: 36640137
Drug: NHS-IL12 16.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NHS-IL12 16.8 µg/kg SC q2w
Study: 36640725
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg AVA treatment
Study: 36640725
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg AVA
Study: 36640794
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (infliximab + immunosuppressant)
Study: 36640794
Drug: Immunosuppressant withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressant withdrawal
Study: 36640862
Drug: Commitment device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commitment device (including daily bidirectional text messages, commitment contract, implementation intentions, support partner involvement)
Study: 36640862
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control (daily bidirectional text messages asking about adherence and weekly messages for weight and blood pressure)
Study: 36640965
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (for all others not undergoing revascularization)
Study: 36641027
Drug: Dog treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog treatment (DT)
Study: 36641093
Drug: Oleclumab 1500
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleclumab 1500 mg (DL1) plus osimertinib 80 mg